- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00704431
A Study With Darapladib to Collect Tolerability Information
November 3, 2016 updated by: GlaxoSmithKline
An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects
Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and the remaining 9 days of dosing will occur at home.
Subjects will record any adverse events throughout the dosing period in a paper diary.
Subjects will return to the CRU 10-14 days after the last dose of darapladib for a follow-up visit.
The total study duration for each subject including the screening, treatment and follow-up periods will be approximately 4 weeks.
Study Overview
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
King of Prussia, Pennsylvania, United States, 19406
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG.
- Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
A female subject is eligible to participate if she is of:
- Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
- Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit.
- Body weight >= 50 kg and BMI within the range 19 - 30 kg/m2 (inclusive).
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- History of drug abuse.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- History of anaphylaxis, anaphylactoid reactions and severe allergic responses.
- History of adult asthma manifested by bronchospasms in the past 6 months or currently taking regular anti-asthmatic medication.
- Currently receiving oral or injectable strong CYP3A4 inhibitor(s).
- Consumption of grapefruit or grapefruit juice within 7 days prior to first dose of study medication.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum hCG test at screening.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: darapladib
|
160 mg darapladib
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events as reported by subjects.
Time Frame: From dosing through to follow-up visit.
|
From dosing through to follow-up visit.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (Actual)
October 1, 2008
Study Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
June 20, 2008
First Submitted That Met QC Criteria
June 20, 2008
First Posted (Estimate)
June 24, 2008
Study Record Updates
Last Update Posted (Estimate)
November 4, 2016
Last Update Submitted That Met QC Criteria
November 3, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LPL111814
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Individual Participant Data Set
Information identifier: LPL111814Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: LPL111814Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: LPL111814Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: LPL111814Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: LPL111814Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: LPL111814Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on SB-480848 (darapladib)
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAtherosclerosisNetherlands, Belgium, Germany, Czechia, France, Austria, Spain, Norway, Poland, Denmark, Switzerland
-
GlaxoSmithKlineThe TIMI Study GroupCompletedAcute Coronary SyndromeUnited States, France, Netherlands, Ukraine, Germany, Taiwan, Bulgaria, Hungary, Poland, Russian Federation, Argentina, Belgium, Peru, Philippines, Sweden, Thailand, Israel, Spain, Korea, Republic of, Australia, Czechia, Japan, New... and more
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAtherosclerosisUnited States, Germany, Estonia, Spain, Argentina, Canada, France, Netherlands, Australia, Bulgaria, Romania, Hungary, Denmark, India, New Zealand, Pakistan
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAtherosclerosisUnited States
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline; National...CompletedEndothelial DysfunctionUnited States
-
GlaxoSmithKlineCompletedRetinopathy, DiabeticAustralia, Netherlands, Italy, Germany, Denmark
-
University of NebraskaNational Cancer Institute (NCI)Withdrawn